Streetwise Reports' Article Archives — September 2020 back to current month (29)
The investment thesis for CloudMD Software & Services is presented in a Mackie Research Capital Corp. report.
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19.
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin.
Genetron Holdings Ltd. shares traded 25% higher after the company reported it has received Breakthrough Device Designation from the FDA for its blood-based next-generation sequencing test for early hepatocellular carcinoma detection.
Shares of Aptorum Group Ltd. traded nearly 300% higher after the company reported it launched an infectious disease liquid biopsy start-up subsidiary.
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test.
Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021.
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2.
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report.
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies.
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands.
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress.
Revive Therapeutics provides an update on its psychedelics therapeutics programs.
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial.
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data.
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients.
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report.
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease.
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy.
Virtual care company American Well Corp., which operates under the name Amwell®, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL.
Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash.
All three brokerage firms that cover the rapidly expanding CloudMD Software & Services rate the company a Speculative Buy, and now the company has gained a toehold in the U.S.
Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels.
Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy.
The specifics of the deal and the next steps for CryoLife are presented in a Ladenburg Thalmann report.
Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc.
The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report.
Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder.
Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19.
|"Momentum continues to build for VIV."|